Two Versus One COVID-19 Vaccine Dose After Prior SARS-CoV-2 Infection: A Nationwide Retrospective Cohort Study

Clicks: 14
ID: 329493
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #259 of 316 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 316 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Immune protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) varies by prior infection and vaccination history. This study evaluated whether two coronavirus disease (COVID-19) vaccine doses after prior infection provide additional protection compared with a single dose. Methods A national matched retrospective cohort study was conducted in Qatar from December 1, 2020–March 3, 2025. Incidence of SARS-CoV-2 reinfection and severe COVID-19 at reinfection was compared between 61,854 previously infected individuals who completed primary-series vaccination (two-dose cohort) and 61,854 matched individuals who received a single dose (single-dose cohort). Results After 360 days of follow-up, cumulative incidence of reinfection was 5.0% (95% CI, 3.8–6.7%) in the two-dose cohort and 7.7% (95% CI, 6.1–9.6%) in the single-dose cohort. No reinfections progressed to severe, critical, or fatal COVID-19 in either cohort. Relative vaccine effectiveness (rVE) of two doses versus one dose was 38.9% (95% CI, 20.4–53.2%). rVE was 26.9% (95% CI, −12.7–53.4%) within <24 days, 51.8% (95% CI, 19.2–71.2%) during days 24–179, and 36.8% (95% CI, 0.9–59.7%) at ≥180 days of follow-up. Subgroup analyses by time between prior infection and vaccination, prior infection variant, and vaccine type yielded broadly similar rVE estimates, while analyses stratified by age and clinical vulnerability suggested higher point estimates among older and clinically vulnerable individuals. Conclusion Among individuals with prior infection, completion of primary-series vaccination provided modest additional protection against reinfection compared with a single dose. These findings support risk-based dose-optimization strategies in settings with constrained vaccine supply.
Reference Key
openalex_W7214064473 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Hiam S. Chemaitelly, Houssein H. Ayoub, Peter Valentine Coyle, Patrick Tang, Mohammad Rubayet Hasan, Hadi Mohamad Yassine, Asmaa A. Al Thani, Zaina Al Kanaani, Einas A. Al-Kuwari, Andrew M. Jeremijenko, Anvar Hassan Kaleeckal, Ali Nizar Latif, Riyazuddin Mohammad Shaik, Hanan F. Abdul Rahim, Gheyath K. Nasrallah, Mohamed Ghaith Al‐Kuwari, Adeel Ajwad Butt, Hamad Eid Al‐Romaihi, Mohamed H. Al‐Thani, Abdullatif Al Khal, Laith Jamal Abu-Raddad
Are you one of these authors? Claim your profile
Journal Open forum infectious diseases
Year 2026
DOI
10.1093/ofid/ofag602
URL
https://doi.org/10.1093/ofid/ofag602
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.